Atalanta Therapeutics, a Boston, MA-based company developing RNA interference (RNAi) to treat neurological diseases, raised $75M in Series B funding.
The round was led by EQT Life Sciences, co-led by Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group and existing investor F-Prime Capital. The Series B financing brings Atalanta’s total capital generated to date from financings and partnerships with Genentech and Biogen to USD 240M.
The company intends to use the funds to support Phase 1 clinical trials of its investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease.
Led by CEO Alicia Secor, Atalanta Therapeutics is providing RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that enables RNAi to be deployed as a therapeutic approach throughout the brain and spinal cord.
Commenting on the news, Alicia Secor said: “We’re excited by the support we’ve received from this strong group of investors, led by EQT Life Sciences. This Series B will support a path to the clinic for two programs for serious neurological diseases that today lack disease-modifying therapies: KCNT1-related epilepsy and Huntington’s disease. We’re diligently progressing these medicines toward IND submissions next year so that we can start our Phase 1 trials and reach patients who are waiting.”
FinSMEs
28/01/2025